-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvectis says China grants breakthrough therapy tag to NXP200 for BRAF V600-mutant high-grade glioma

PUBT·09/24/2026 12:06:18
Nuvectis says China grants breakthrough therapy tag to NXP200 for BRAF V600-mutant high-grade glioma
  • China’s drug regulator granted Breakthrough Therapy Designation to Nuvectis-partnered NXP200 for BRAF V600-mutant recurrent or progressive high-grade glioma.
  • NXP200 was developed by Haisco; Nuvectis holds exclusive worldwide rights outside Greater China under a June 2026 licensing deal.
  • Nuvectis targets a US IND filing for NXP200 in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833062) on September 24, 2026, and is solely responsible for the information contained therein.